We sought to interrogate TIGIT expression in ASCT donor products, as clinical studies have reported expression of TIGIT on bone marrow (BM) CD8+ T cells from patients with MM (3, 11) and we have previously shown that preexisting CD8+ T cells in the donor graft provide antimyeloma immunity in preclinical murine models (1). Here, CD8A is linked to Miyoshi myopathy.